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ABSTRACT 
The objective of the study is to determine whether T cell depletion through pretreatment 
with either Thymoglobulin or Campath influences the incidence and severity of PGD (primary 
graft dysfunction) after human lung transplantation. 
This is a single center study, conducted between July 2000 and November 2004, and is a 
retrospective analysis of 206 patients.  Patients received one of following forms of induction 
therapy: Zenapax (n=28), Thymoglobulin (n=37), Campath (n=76), or no induction (n=65) 
therapy.  Donor and recipient demographic, operative information, and survival data were 
collected.  Assignment of primary grading dysfunction (PGD) grading was based on the 
International Society for Heart and Lung Transplantation (ISHLT) grading guidelines. 
While baseline characteristics were similar for most variables, grafts for patients that 
received Campath (293±64 min) or Thymoglobulin (282±66 min) had a longer duration of 
ischemic time compared to the control group, no induction therapy (246±65 min).  A significant 
difference between Campath (78.9%) and no induction (92.3%) group was observed with a p-
value of 0.047 for the overall severity of PGD.  In the multivariate analysis, Perfadex (p=0.009, 
OR=0.31), the preservation solution, remained as a protective agent on preventing recipients 
from severe PGD, and use of CPB (cardiopulmonary bypass) (p<<0.001, OR=4.53) was 
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identified to be a statistically significant risk factor for development of grade 3 PGD.  There was 
improved early oxygenation and improved one year survival in patients that received Campath 
compared to the control group. 
The combined use of Campath as induction therapy and the graft preservation solution of 
Perfadex seem to be protective against the development of grade 3 PGD as their roles on 
defending cumulative incidence of PGD were hindered.  The use of CPB was an independent 
risk factor to the development of grade 3 PGD.  These results suggest that the development of 
PGD after human lung transplantation is mainly due to intrinsic immune or non-immune 
mechanisms, further study will be necessary to unravel the role of T cells, and it will have 
significant impact on public health relevance applications. 
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INTRODUCTION 
Organ transplantation has evolved, and lung transplantation is the only effective choice of 
treatment for end-stage pulmonary diseases.  However, the incidence of primary graft 
dysfunction (PGD), also known as ischemia-reperfusion injury, pulmonary re-implantation 
response, or early allograft failure, is considered to be a significant clinical problem after lung 
transplantation.  Patients who develop PGD require longer recipient intensive care unit stays, 
hospital stays, and prolonged post-operative mechanical ventilation.  PGD is known to be a 
major contributing factor to early mortality after lung transplantation. However, the etiology of 
PGD remains ambiguous and is anticipated to be multi-factorial.  Ischemia-reperfusion (IR) 
injury of the lung is recognized to play a major role in the etiology of PGD. 
Recent studies have shown that T cells may play an important role in IR injury.  A recent 
study conducted by De Perrot and colleagues concluded that recipient T cells mediate the 
pathogenesis of IR injury to the lung (1).  Several studies on small animals suggested that T cells 
play a part in both renal (2-4), hepatic (5-7), and lung IR injury.   
Recipient pre-transplant lymphoid depletion and minimal use of post-transplant 
immunosuppression are two key principles that have been recently employed in clinical lung 
transplantation.  Lymphocyte depletion is meant to pre-operatively deplete pre-existing 
alloreactive donor-specific T cells to prevent acute rejection.  Based on several clinical and 
experimental studies indicating that T cells may take parts in the pathogenesis of IR injury, our 
hypothesis focuses on the use of pre-transplant lymphoid depleting agents in our 
immunosuppressive protocol that might alter the incidence and severity of PGD after human 
lung transplantation.  The measurements to test this hypothesis are the incidence and severity of 
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PGD and early oxygenation in the consecutive lung transplant recipients from UPMC; these 
recipients would either receive one of four induction therapies: Zenapax, Thymoglobulin, 
Campath, or no induction therapy. 
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MATERIALS AND METHODS 
PATIENTS 
This is a single center study, which was conducted between July 2000 and November 
2004.  Consecutive adult patients who underwent single lung, double lung, or heart-lung 
transplantation were analyzed.  Patients with combined liver-lung transplantation were excluded 
from the study due to confounded PGD grading of accompanying liver transplantation.  The 
death of one patient occurred in the course of operation was excluded because no PGD grading 
could be performed.   
INFORMED CONSENT 
All patients provided standard written informed consent in addition to consent for 
enrollment and participation in an IRB approved protocol and for reporting of outcomes. 
INDUCTION PROTOCOLS 
The induction protocols and subsequent immunosuppressive methods adopted in this 
study were formerly detailed (8).  Patients received one of the following induction therapies: 
Zenapax, Thymoglobulin, Campath, or no induction therapy.  The infusion of antibody was 
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initiated once donor organs were validated for transplantation.  Four to seven mg/kg 
Thymoglobulin was administered to 37 patients between 6/02 and 9/03; Thymoglobulin 
infusions were commenced slowly and the infusion rate was increased every thirty minutes.  
Thirty milligrams of intravenous Campath was administered to 76 patients between 1/03 and 
11/04.  Patients treated with either Thymogolbulin or Campath were co-administered with 1g of 
methylprednisolone.  Before lung allograft reperfusion, 250mg of methylprednisolone was given 
as well.  One dose (1mg/kg) of Zenapax on the day of transplantation was administered to 28 
patients between 11/01 and 6/02; four more doses on post-transplant day seven and post-
transplant two, four, and six doses were administered to those patients subsequently.  
DATA COLLECTION 
Donor and recipient demographic, operative information, and survival data were 
collected prospectively.  Donor smoking history, PaO2/FiO2 (partial pressure of arterial oxygen 
to fraction of inspired oxygen concentraion ratio) ratio, and sputum culture results were 
ascertained from donor charts from the local organ procurement organization retrospectively.  
Duration of mechanical ventilation, duration of inhaled nitric oxide (iNO), use of extra-corporeal 
membrane oxygenation (ECMO), post-operative pulmonary function including PaO2/FiO2 ratio 
were ascertained from the electronic health record. 
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PGD GRADING 
Assignment of primary grading dysfunction (PGD) grading was performed in accordance 
to the International Society for Heart and Lung Transplantation (ISHLT) grading guidelines (9).  
Grade 0 was assigned to patients with PaO2/FiO2 ratio greater than 300 and the absence of 
radiographic infiltrates.  Grade 1 was assigned to patients with PaO2/FiO2 ratio greater than 300 
and the presence of radiographic infiltrates.  Based on patient’s chest radiograph, one was 
assigned with grade 0 or grade 1 if extubated and on nasal cannula.  Grade 2 was assigned to 
patients with PaO2/FiO2 ratio between 200 and 300.  Grade 3 was assigned to patients with 
PaO2/FiO2 ratio less than 200.  Patients who were mechanically ventilated with FiO2 greater than 
0.5, received iNO for greater than 48 hours, and were on ECMO were assigned grade 3.  Six and 
12 hour time-points were included in addition to recent proposed potential refinements to the 
ISHLT guidelines. 
STATISTICAL ANALYSIS 
The donor and recipient characteristics included in the analysis were as follows: 
demographic and personal characteristics, diagnosis of primary pulmonary hypertension (PPH), 
cardiopulmonary bypass (CPB), mean pulmonary arterial pressure (mean PA), smoking history, 
cause of donor death, Perfadex (preservation solution), sputum culture results, donor ratio of 
arterial oxygen tension to inspired oxygen fraction (PaO2 /FiO2), 1st/2nd lung ischemic time, 
cytomegalovirus (CMV) mismatch, recipient blood type, and ECMO.   
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The association of donor and recipient characteristics with severe primary graft 
dysfunction after lung transplant was analyzed by using binary logistic regression models.  
Nominal variables were expressed as counts and proportions.  The outcome variables (PGD 
grading) were expressed in a binary fashion, such that a baseline group of patients with PGD0 
and PGD1 compares to patients with PGD2 and PGD3.  Two types of outcome variables were 
analyzed: the first type includes patients with PGD2 and PGD3, and the second type of outcome 
variable includes only PGD3 patients.  Type I error was set to be statistically significant if p-
value is less than or equal to 0.05 (two-tailed p-value).   
Donor and recipient (independent) variables were screened on a univariate basis, and those that 
were statistically significant were used in multivariate logistic regression models to adjust for 
potential confounding.   Survival estimates were derived by using the Kaplan-Meier method, and 
survival across the induction groups were compared by using the log-rank test.  Analyses were 
performed with Minitab for Windows, Version 15 (Minitab Inc, State College, PA). First 
paragraph. The figure below is inserted so that there is an item in the sample List of Figures. 
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RESULTS 
A total of 206 patients were analyzed, 93 patients (45%) experienced  PGD 1 or less, 39 
patients (19%) developed PGD2, and 74 patients (36%) developed PGD3.  In the single and 
double transplantation groups, 54 patients (51%) and 55 patients (57%) developed PGD2 or 
PGD3, respectively.   
DONOR DEMOGRAPHICS 
Donor characteristics are summarized in Table 1.  Donor age, sex, cause of death, 
PaO2/FiO2, smoking history, sputum, and CMV mismatch were similar (p>0.05) among groups.  
The use of preservation solution of Perfadex and 1st lung ischemic time differed between 
induction groups.  Among grafts preserved in Perfadex, 49% of patients underwent Campath 
induction; 41% underwent either Thymoglobulin or Zenapax; 10% patients were in no induction 
group (control group).  Preservation solutions other than Perfadex, such as UW, Celsior, or Euro-
Collins, were used in remainder of patients.  Most patients who received Campath or 
Thymoglobulin had longer duration of ischemic time compared to the control group.  While the 
p-value for donor PaO2/FiO2 was border line significant (p=0.08), a trend of lower PaO2/FiO2 
was observed among patients received Campath.   
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RECIPIENT DEMOGRAPHICS AND OPERATIVE CHARACTERISTICS 
Recipient and operative characteristics are described in Table 2.  Differences in  recipient 
age, sex, race, blood type, mean PA (pulmonary artery) pressure, laterality, and CPB 
(cardiopulmonary bypass) were not statistically significant (p>0.05) across induction groups.  
Type of transplantation, such as single lung, double lung, or heart-lung transplant differed 
between groups.  Among those 206 recipients, 105 patients (51%) received single lung 
transplantations, 97 patients (47%) received double lung transplantations, and 4 patients (2%) 
received heart-lung transplantations.  Most patients (45%) in the double lung transplant group 
received Campath, whereas 44% of patients in the single lung transplant received no induction.  
Within the Campath group, 58 patients (76%) did not use CPB. 
POST-OPERATIVE RECIPIENT CHARACTERISTICS 
The duration and proportion of patients requiring mechanical ventilation at six time 
points, T0, T6, T12, T24, T48, and T72, were evaluated in Table 3.  The differences in duration 
of mechanical ventilation across four induction methods were not statistically significant at T0, 
T6, T48, and T72; however, statistically significant differences between induction therapies in 
duration of mechanical ventilation were observed at T12 and T24 (p<0.05).  In the 
Thymoglobulin group, 37 patients (100%) were on mechanical ventilation between T0 to T12, 
and 30 patients (81.1%) required the mechanical ventilation at T24.  At T12, 65 out of 76 
patients (85.5%) in the Campath group stayed on the mechanical ventilation, compared to 26 
patients (92.8%) in the Zenapax and 50 patients (76.9%) in the control group, received no 
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induction.  At T24, 38 patients (50%) received Campath required the mechanical ventilation, 
whereas 30 patients (81.1%) in the Thymoglobulin group, 19 patients (67.9%) in the Zenapax 
group and 37 patients (56.9%) in the control group.  The median duration in hours across four 
induction methods was not statistically significant (p=0.064).  Among each induction group, the 
use of Campath contributed the lowest median duration in hours compared to the other induction 
methods, or no induction group. 
Post-operative recipient oxygenation characteristics at six time points are summarized in 
Table 4.  Mean PaO2/FiO2 ratios for patients, excluding patients that were treated with ECMO 
(extra-corporeal membrane oxygenation), were evaluated.  The mean PaO2/FiO2 ratios had no 
statistically significant differences observed at T0, T24, T48, and T72 but displayed statistically 
significant differences at time point T6 and T12 (p<0.05).  At T6 and T12, the mean PaO2/FiO2 
ratios in Campath group were similar and increased while the ratios remained low for other 
induction methods.  However, the highest mean PaO2/FiO2 ratio was observed in Thymoglobulin 
therapy at T48, at which no significant differences between induction groups was observed. 
The use of post-operative inhaled nitric oxide (iNO) and ECMO for patients was 
tabulated in Table 5.  Patients on iNO, median duration of iNO in hours, and patients on ECMO 
were evaluated across four induction methods.  A significant difference in patients on iNO 
between induction methods was observed (p<<0.001) while no statistically significant 
differences observed in patients on ECMO or median duration of iNO in hours.  More patients 
who received Thymoglolulin were on iNO than that of those received Campath.   
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INCIDENCE AND SEVERITY OF PRIMARY GRAFT DYSFUNCTION 
The incidence and severity of PGD were detailed in Table 6.  The severity of PGD, 
categorized into four grading scales, 0, 1, 2, 3, was measured between groups of induction 
therapies.  Across the four induction methods, the incidence of grade 0 PGD was statistically 
significant (p=0.047) as well as the incidence of grade 3 PGD (p=0.009).  In grade 0 PGD, there 
were 16 new cases (21.1%) observed in the Campath group and 5 new cases (7.7%) observed in 
the control group, no induction.  Grade 1 and 2 PGD displayed no statistically significant 
differences in incidence between groups.  For grade 3 PGD group (p=0.009), no induction 
method (47.7%) had higher incidence compared to patients with Campath method (25%).  
Overall, a significant difference between Campath (78.9%) and no induction (92.3%) group was 
observed with a p-value of 0.047.  Of patients in the no induction group receiving graft preserved 
with Perfadex (n=16), incidence of grade 3 PGD is 37.5% (6 patients) and overall incidence of 
PGD is 93.8% (15 patients).   
A univariate binary logistic analysis on development of grade 3 PGD and grade 2 or 3 
PGD are summarized in Table 7.  The use of Campath (p=0.013, OR=0.45) as an induction 
therapy has prevented patients from developing severe grade 3 PGD, as well as the use of 
Perfadex (p=0.011, OR=0.43) as a graft preservation solution.  Variables such as recipient 
diagnosis of primary pulmonary hypertension (PPH; p=0.015, OR=13.69), use of 
cardiopulmonary bypass (CPB; p<<0.001, OR=4.47), elevated recipient mean pulmonary arterial 
pressure (mean PA; p=0.029, OR=2.01), and negative donor sputum cultures (p=0.040, 
OR=3.09) were identified as risk factors for the development of severe PGD3 grading.  In the 
development of grade 2 or 3 PGD, use of Campath (p=0.026, OR=0.52) and Perfadex (p=0.512, 
OR=0.81) were protective against the development of PGD2 or PGD3, and the risk factors were 
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CPB (p<<0.001, OR=4.93), elevated recipient mean PA pressure (p=0.026, OR=1.95), and 
negative donor sputum cultures (p=0.045, OR=2.61).   
A multivariate analysis on development of grade 3 PGD is summarized in Table 8.  
Perfadex (p=0.009, OR=0.31), the preservation solution, remained as a protective agent on 
preventing recipients from severe PGD, and use of CPB (p<<0.001, OR=4.53) was identified to 
be a statistically significant risk factor for development of PGD3.  In addition, a multivariate 
analysis in Table 9 has indicated that CPB (p<<0.001, OR=4.44) was a risk factor for the 
development of grade 2 or 3 PGD.  Results of multivariate analysis for patients who received no 
induction therapies are shown in Table 10, Perfadex was indentified to be an safeguard (p=0.001, 
OR=0.26) on developing severe PGD grade 3, while CPB (p=<<0.001, OR=4.64) persisted as a 
statistically significance as a risk factor on the progression of grade 3 PGD.   In Table 11, the 
significant risk factor of CPB (p<<0.001, OR=4.56) was associated with the development of 
grade 2 or 3 PGD. 
PATIENT SURVIVAL 
A cumulative proportion of patient survival analysis on patients with PGD 3 grading was 
performed.  Patients with no induction therapy displayed a trend toward early mortality 
compared to the groups with other induction methods (Figure 1).  A statistically significant 
difference was observed for patient survival between the control group and Campath group via a 
Log-Rank test (p=0.034).  For patients received Campath therapy, they would have less risk of 
developing PGD 1 or higher in a year compared to patients received other induction methods.  It 
is shown in Figure 2 that survival for patients received Campath was higher than that of the 
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control group; 90.79% of patients received Campath survived after 1 year compared to 75.38% 
of patients received no induction therapy.  The patient survival between Campath and the control 
group was statistically significant (p=0.009 by Log-Rank test) over time.   
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DISCUSSION 
This study suggested that a cohort of lung transplant patients who received Campath, as 
induction therapy show some improvement in early oxygenation compared to patients who 
received no induction therapy, despite longer ischemic times.  As a result, patients in the 
Campath group were less likely to develop grade 3 PGD or PGD overall.    Nevertheless, while 
Campath was screened in a univariate analysis and identified to be effective against the 
development of severe PGD, it was not a statistically significant factor in the multivariate 
analysis.  There appeared to be improved 1 year survival in patients that received Campath, 
although a long term survival benefit could not be conclusively demonstrated in this analysis.  
Moreover, despite a low incidence of PGD3 (25.0%) in Campath group, the overall incidence of 
PGD (78.9%) remained high for patients in Campath group.  
It has been demonstrated that Campath extensively depletes T cells. Our data reveals a 
substantial incidence of PGD despite lymphocyte depletion with Campath therefore, 
development of PGD after human lung transplantation may be  largely due to intrinsic immune 
or non-immune mechanisms.  The role of T cells in the development of PGD in this study has 
not been precluded.  The development of PGD is likely multi-factorial.  Indeed, further study 
will be necessary to unravel the role of T cells in the pathogenesis of PGD in human lung 
transplantation. 
In our study, Perfadex played an effective role against the progression of grade 3 PGD.  
When taking account of the entire cohort in a multivariate analysis and in a subgroup analysis on 
patients that received no induction therapy, the effect of Perfadex on preventing patients from 
development of PGD 3 grading was seen.  Although used in our study, the application of 
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Perfadex as a graft preservation solution in clinical lung transplantation has been debated 
throughout the literature.  Some studies found little benefit of this preservation solution for 
transplanted lung (10-13), whereas other studies have found exceptional efficacy of Perfadex as a 
preservation solution when measuring clinical outcomes after human lung transplantation, 
including improved post-operative oxygenation (14-17), compared to other preservation 
solutions. 
In our study, CPB was identified to be a statistically significant predictive factor for the 
development of PGD in general.  While CPB may contribute to the development of PGD by a 
number of mechanisms, it has been known to contribute to the pathogenesis of acute lung injury, 
such as increased expression of adhesion molecules on endothelial cells, pro-inflammatory 
cytokine release, complement activation, neutrophil activation, and others (18-19).  This finding 
is consistent with least one other study (30) that demonstrated that CPB was a predictive factor 
of the development of PGD; however, other large studies have not implicated the involvement of 
CPB on the development of PGD (20-21).   
Several previous studies have identified a number of risk factors to the development of 
grade 3 PGD, inclusive of donor age, donor female gender, donor African-American race, 
recipient PA pressure, recipient diagnosis of PPH, and transplantation era.  In our univariate 
analysis of the development of grade 3 PGD, elevated mean PA pressure and recipient diagnosis 
of PPH were identified to be significant risk factor; however, they did not turn out to be 
significant in the multivariate analysis.  Possible reasons for this difference could be the design 
of study and small sample size of patient population.  
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CONCLUSION 
While induction therapy with Campath and the graft preservation solution Perfadex 
appear to be effective factors against the development of grade 3 PGD, their roles on preventing 
cumulative incidence of PGD were hindered.  The use of cardiopulmonary bypass (CPB) was an 
independent risk factor for the development of grade 3 PGD, as well as for grade 2 or 3 PGD, in 
both univariate and multivariate analysis.  Accordingly, the development of PGD was evidently 
multi-factorial.  Nevertheless, the role of T cells in progression of PGD of human lung 
transplantation requires further investigation, though it may have played a role in our study.  Our 
study inherited some possible limitations due to the use of consecutively enrolled patients, its 
retrospective nature, and restrictive sample size.  A randomized, controlled clinical trial will be 
required to better assess the nature of Campath and other induction agents in the development of 
PGD after human lung transplantation. 
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Table 1: DONOR CHARACTERISTICS 
 Control – 
No Induction 
Zenapax Thymoglobulin Campath P value 
N 65 28 37 76  
Donor Age 
(years) 
37.7 + 14.3 
 
36.1 + 14.8 
 
33.5 + 14.6 
 
34.1 + 14.2 
 
0.400 
Donor Sex 
     Male 
     Female 
 
 
36 (55.4%) 
29 (44.6%) 
 
12 (42.9%) 
16 (57.1%) 
 
17 (45.9%) 
20 (54.0%) 
 
46 (60.5%) 
30 (39.5%) 
 
0.428 
Cause of Death 
     Trauma 
     Cerebrovascular 
     Other 
 
33 (50.8%) 
30 (46.1%) 
2 (3.1%) 
 
14 (50.0%) 
14 (50.0%) 
0 (0.0%) 
 
19 (51.4%) 
17 (45.9%) 
1 (2.7%) 
 
 
33 (43.4%) 
39 (51.3%) 
4 (5.3%) 
 
 
0.917 
 
Donor PaO2/FiO2 
(mm Hg) 
437.4 + 84.0 453.0 + 109.9 441.2 + 89.0 407.1 + 96.1 0.080 
Preservation Solution 
     Perfadex 
     UW 
     Celsior 
     Euro-Collins 
     Other/unknown 
 
 
 
16 (24.6%) 
4 (6.2%) 
25 (38.5%) 
9 (13.8%) 
11 (16.9%) 
 
 
26 (92.9%) 
1 (3.6%) 
0 (0.0%) 
1 (3.6%) 
0 0.0 %) 
 
 
37 (100%) 
0 (0%) 
0 (0%) 
0 (0%) 
0 (0%) 
 
 
76 (100%) 
0 (0%) 
0 (0%) 
0 (0%) 
0 (0%) 
 
 
 
< 0.001 
 
 
Ischemic Time 
     1st lung 
     2nd lung 
     (minutes) 
 
236 + 64.7 
359 + 76.0 
 
269 + 61.6 
366 + 69.2 
 
282 + 66.4 
417 + 73.6 
 
 
293 + 64.1 
384 + 75.3 
 
< 0.01 
0.113 
Smoking History 
     Any 
     10 Pack-Year 
 
 
36 (55.4%) 
23 (35.4%) 
 
 
20 (71.4%) 
10 (35.7%) 
 
20 (54.1%) 
14 (37.8%) 
 
44 (57.8%) 
18 (23.7%) 
 
0.626 
0.420 
Donor Cultures 
     Positive 
     Negative 
     No data 
 
 
27 (41.5%) 
32 (49.2%) 
6 (9.2%) 
 
13 (46.4%) 
13 (46.4%) 
2 (7.1%) 
 
19 (51.4%) 
16 (43.2%) 
2 (5.4%) 
 
27 (35.5%) 
42 (55.3%) 
7 (9.2%) 
 
0.926 
CMV Mismatch 
 
18 (27.7%) 5 (17.9%) 12 (32.4.0%) 15 (19.7%) 0.521 
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Table 2: RECIPIENT AND OPERATIVE CHARACTERISTICS 
 Control- 
No 
Induction 
Zenapax Thymoglobulin Campath P 
value 
N 65 28 37 76  
Age (yrs) 52.5 + 10.2 
 
51.2 + 13.0 
 
48.2 + 12.6 52.1 + 12.8 
 
0.452 
Sex 
     Male 
     Female 
 
38 (58.5%) 
27 (41.5%) 
 
13 (46.4%) 
15 (53.6%) 
 
16 (43.2%) 
21 (56.8%) 
 
40 (52.6%) 
36 (47.4%) 
 
 
0.591 
Race 
     Caucasian 
     African-American 
     American Indian 
     Hispanic 
     Pacific Islander 
 
60 (92.3%) 
3 (4.6%) 
0 (0.0%) 
1 (1.5%) 
1 (1.5%) 
 
 
27 (96.4%) 
0 (0.0%) 
1 (3.6%) 
0 (0.0%) 
0 (0.0%) 
 
 
35 (94.6%) 
2 (5.4%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
 
 
72 (94.7%) 
4 (5.3%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
 
 
0.833 
Blood Type 
     A 
     B 
     AB 
     O 
 
21 (32.3%) 
 7 (10.8%) 
5 (7.7%) 
32 (49.2%) 
 
17 (60.7%) 
1 (3.6%) 
1 (3.6%) 
 9 (32.1%) 
 
16 (43.2%) 
4 (10.8%) 
0 (0%) 
17(45.9%) 
 
35 (46.0%) 
11 (14.5%) 
1 (1.3%) 
29 (38.2%) 
 
 
0.264 
Indication 
     Emphysema/COPD 
     IPF 
     CF 
     α-1-anti-trypsin 
     Scleroderma/CREST 
     PPH 
     Sarcoidosis 
     Bronchiolitis obliterans 
     Silicosis 
     Eisenmenger 
     MCTD 
     Rheumatoid 
     Graft vs. Host Disease 
     Pulmonary fibrosis 
     Eosinophilc granuloma     
     Other 
 
27 (41.5%) 
9 (13.8%) 
7 (10.8%) 
2 (3.1%) 
2 (3.1%) 
5 (7.7%) 
3 (4.6%) 
0 (0.0%) 
4 (6.2%) 
1 (1.5%) 
1 (1.5%) 
2 (3.1%) 
0 (0.0%) 
1 (1.5%) 
0 (0.0%) 
1 (1.5%) 
 
10 (35.7%) 
8 (28.6%) 
4 (14.3%) 
1 (3.6%) 
2 (7.1%) 
0 (0.0%) 
0 (0.0%) 
1 (3.6%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
1 (3.6%) 
0 (0.0%) 
0 (0.0%) 
1 (3.6%) 
 
12 (32.4%) 
5 (13.5%) 
7 (18.9%) 
5 (13.5%) 
2 (5.4%) 
1 (2.7%) 
2 (5.4%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
1 (2.7%) 
0 (0.0%) 
0 (0.0%) 
1 (2.7%) 
1 (2.7%) 
0 (0.0%) 
 
23 (30.3%) 
19 (25.0%) 
 8 (10.5%) 
6 (7.9%) 
4 (5.3%) 
2 (2.6%) 
3 (3.9%) 
7 (9.2%) 
0 (0.0%) 
0 (0.0%) 
1 (1.3%) 
0 (0.0%) 
1 (1.3%) 
1 (1.3%) 
0 (0.0%) 
1 (1.3%) 
 
 
0.433 
Recipient Mean PA Pressure 29.9 + 11.2 27.0 + 6.5 29.8 + 8.8 28.5 + 10.4 0.737 
Type 
     Single 
     Double 
     Heart-lung 
 
46 (70.8%) 
18 (27.7%) 
1 (1.5%) 
 
13 (46.4%) 
15 (53.6%) 
0 (0.0%) 
 
17 (45.9%) 
20 (54.0%) 
0 (0 %) 
 
29 (38.2%) 
44 (47.3%) 
3 (3.2%) 
 
 
0.003 
Laterality 
     Left 
     Right 
     Bilateral 
 
 
27 (41.5%)  
19 (29.2%)  
19 (29.2%) 
 
6 (21.4%) 
7 (25.0%) 
15 (53.6%) 
 
9 (24.3%) 
8 (21.6%) 
20 (54.1%) 
 
21 (27.6%) 
8 (10.5%) 
47 (61.8%) 
 
0.477 
Redo 0 (0.0%) 1 (3.6%) 0 (0.0%) 6 (7.9%) 0.051 
CBP 16 (24.6%) 11 (39.3%) 10 (27.0%) 18 (23.4%) 
 
0.451 
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Table 3: PATIENTS REQUIRING MECHANICAL VENTILATION AND 
MEDIAN DURATION OF MECHANICAL VENTILATION 
 TO T6 T12 T24 T48 T72 Median duration in hours 
(interquartile range) 
Control –  
No Induction 
 
65 
(100%) 
61 
(93.8%) 
50 
(76.9%) 
37 
(56.9%) 
29 
(44.6%) 
23 
(35.4%) 
35.1 
(14.5-96.3) 
Zenapax 
 
28 
(100%) 
28 
(100%) 
26 
(92.8%) 
19 
(67.9%) 
18 
(64.3%) 
14 
(50.0%) 
58.8 
(20.5-121) 
Thymoglobulin 37  
(100 %) 
37 
(100 %) 
37 
(100 %) 
30 
(81.1%) 
19 
(51.4%) 
15 
(40.5%) 
50.0 
(25.5-107) 
 
Campath  76 
(100 %) 
75 
(98.7%) 
65 
(85.5%) 
38 
(50.0%) 
26 
(34.2%) 
22 
(28.9%) 
21.45 
(14.0-68.9) 
 
P value n.s. 0.2401 0.0181 0.026 0.056 0.318 0.064 
 
 
 
 
 
 
Table 4: POST-OPERATIVE RECIPIENT MEAN PAO2/FIO2 VALUES  
(EXCLUDING ECMO PATIENTS) 
 TO T6 T12 T24 T48 T72 
Control- 
No Induction 
 
274.51 
+ 153.89 
227.21 
+ 102.32 
211.41 
+ 81.40 
222.11 
+108.89 
225.38 
+ 74.40 
150.25 
+ 11.08 
Zenapax 
 
264.43 
+128.05 
218.65 
+104.54 
246.50 
+118.23 
228.02 
+ 98.00 
245.57 
 + 90.30 
182.55 
+ 70.05 
Thymoglobulin 288.54 
+140.34 
 
224.59 
+ 91.57 
 
239.70 
+102.81 
 
264.42 
+ 104.89 
 
310.50 
+124.01 
 
194.55 
+ 00.00 
 
Campath  274.88 
+113.53 
 
303.10 
+ 288.49 
 
305.75 
+ 77.47 
 
298.19 
+ 104.95 
 
227.24 
+74.54 
 
198.66 
+ 44.19 
 
P value 0.969  0.018  0.002 0.221 0.268 0.581 
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Table 5: USE OF POST-OPERATIVE INHALED NITRIC OXIDE (INO) AND 
EXTRA-CORPOREAL MEMBRANE OXYGENATION (ECMO) 
 Patients 
on iNO 
Median Duration of 
iNO in hours 
(interquartile range) 
Patients on 
ECMO 
Control- 
No Induction 
 
23 
(35.4%) 
42.68 
(26.48-73.86) 
7 
(10.8%) 
Zenapax 
 
13 
(46.4%) 
38.17 
(30.41-69.76) 
2 
(7.1%) 
Thymoglobulin 23 
(62.2%) 
41.68 
(24.75-50.95) 
 
2 
(5.4%) 
Campath  12 
(15.8%) 
36.61 
(8.11-45.85) 
 
6 
(7.9%) 
P value <0.001 0.549 0.892 
 
 
 
 
 
Table 6: INCIDENCE AND SEVERITY OF PGD 
 PGD 0 PGD I PGD II PGD III Overall 
Control- 
No Induction 
 
5 
(7.7%) 
21 
(32.3%) 
8 
(12.3%) 
 
31 
(47.7%) 
60 
(92.3%) 
 
Zenapax 
 
4 
(14.3%) 
6 
(21.4%) 
7 
(25.0%) 
11 
(39.3%) 
24 
(85.7%) 
Thymoglobulin 5 
(13.5%) 
10 
(27.0%) 
10 
(27.0%) 
12 
(32.4%) 
32 
(86.4%) 
 
Campath  16 
(21.1%) 
26 
(34.2%) 
15 
(19.7%) 
19 
(25.0%) 
60 
(78.9%) 
 
P value 0.047 0.579 0. 683 0. 009 0.047 
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 Table 7: UNIVARIATE ANALYSIS 
 PGD23 
p-value (odds ratio) 
PGD3 
p-value (odds ratio) 
Induction 0.037 (1.32) 0.018 (1.38) 
2grp_Campath 
1 
 
0.026 (0.52) 
 
0.013 (0.45) 
Donor age (yrs) 0.966 (1.00) 0.675 (1.00) 
Recipient age (yrs) 0.120 (0.98) 0.129 (0.98) 
Donor gender 0.054   (0.58) 0.157   (0.66) 
Recipient gender 0.111   (0.64) 0.115   (0.63) 
PPH 0.998 (1.45159E+09)* 0.015 (13.69) 
CPB 0.000 (4.93) 0.000 (4.47) 
Mean PA 0.004 (1.05) 0.012 (1.04) 
Mean PA_25 0.026 (1.95) 0.029 (2.01) 
Perfadex 0.512   (0.81) 0.011   (0.43) 
Tx (single double H-L) 
2 
3 
 
0.453 (1.24) 
0.999 (1.54785E+09)* 
 
0.574 (1.18) 
0.127 (6.00) 
Tx (single double) 
2 
 
0.453 (1.24) 
 
0.574 (1.18) 
Smk 
1 
2 
 
0.858 (0.94) 
0.110 (1.71) 
 
0.297 (0.66) 
0.281 (0.44) 
Cause of death 
1 (cerebrovascular) 
2  (other)  
 
0.786   (0.92) 
0.813   (0.88) 
 
0.598   (1.17) 
0.922   (1.06) 
Sputum(0 N/A)  
1 (Negative)  
2  (Positive) 
 
0.045   (2.61) 
0.307   (1.62) 
 
0.040   (3.09) 
0.468   (1.50) 
Donor PaO2/FiO2 0.650   (1.00) 0.258   (1.00) 
Ischemic_1stLung 0.512   (1.00) 0.541   (1.00) 
Ischemic_2ndLung 0.146   (1.00) 0.978   (1.00) 
CMV Mismatch (no/yes : 0/1) 0.230   (1.49) 0.509   (1.25) 
Recipient Race 
0 (Caucasion) 
1 (African-American)  
2 (other) 
 
 
0.482   (1.66) 
0.476   (0.42) 
 
 
0.589   (1.45) 
0.936   (0.91) 
Recipient Blood Type 
2 
3 
4 
 
 
0.962   (0.98) 
0.738   (1.30) 
0.220  (1.45) 
 
 
0.866   (0.92) 
0.625   (1.48) 
0.459   (1.26) 
Laterality 
2 
3 
4 
 
0.811      (0.91) 
0.999  (1.48991E+09)* 
0.592         (1.19) 
 
0.673   (1.19) 
0.116   (6.45) 
0.487   (1.27) 
Redo (no/yes : 0/1) 0.520   (0.61) 0.681   (0.71) 
ECMO (no/yes : 0/1) 0.997  (1.58768E+09)* 0.997  (4.42989E+09)* 
*Large odds ratio observed is due to the small sample size. 
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Table 8: MULTIVARIATE ANALYSIS FOR PGD3 
 p-value (odds ratio) 
PPH 0.135   (5.57) 
CPB 0.000   (4.53) 
MeanPA_25 0.082   (1.87) 
2grp_Campath 0.391   (0.71) 
Perfadex 0.009   (0.31) 
Sputum 
1 
2 
 
0.123   (2.80) 
0.795   (1.19) 
 
 
 
 
 
 
Table 9: MULTIVARIATE ANALYSIS FOR PGD 23 
 p-value (odds ratio) 
Perfadex 0.572   (0.78) 
CPB 0.000   (4.44) 
 
MeanPA_25 0.074   (1.79) 
2grp_Campath 0.109   (0.56) 
Sputum 
1 
2 
 
0.068   (2.85) 
0.403   (1.61) 
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Table 10: MULTIVARIATE ANALYSIS FOR PGD 3 (NO INDUCTION) 
 p-value (odds ratio) 
PPH 0.135   (5.53) 
 
CPB 0.000   (4.64) 
 
MeanPA_25 0.070   (1.92) 
 
Perfadex 0.001   (0.26) 
Sputum 
1 
2 
 
0.113   (2.86) 
0.745   (1.24) 
 
 
 
 
 
Table 11: MULTIVARIATE ANALYSIS FOR PGD 23 (NO INDUCTION) 
 p-value (odds ratio) 
CPB 0.000   (4.56) 
MeanPA_25 0.058   (1.85) 
Perfadex 0.178   (0.58) 
Sputum 
1 
2 
 
0.054   (2.96) 
0.306   (1.78) 
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Figure 2: PATIENT SURVIVAL IN 365 DAYS 
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